Arvinas plans to initiate two Phase 3 trials in 2025 for vepdegestrant in ER+/HER2- metastatic breast cancer, one in the first-line setting with atirmociclib and another in the second-line setting with a CDK4/6 inhibitor.
The FDA issued 16 oncology approvals between July and September 2024, addressing the global surge in cancer cases, particularly among individuals under 50.
Enliven Therapeutics announced updated Phase 1 data for ELVN-001, presented at the ESH-iCMLf conference, showing clinical benefit in heavily pretreated CML patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.